Gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate‐ and high‐risk prostate cancer

Objective To determine the value of gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA)‐11 positron emission tomography (PET) /computed tomography (CT) in men with newly diagnosed prostate cancer. Patients and methods We analysed results of 140 men with intermediate‐ and high‐risk prostate can...

Full description

Saved in:
Bibliographic Details
Published in:BJU international 2019-07, Vol.124 (1), p.62-68
Main Authors: Leeuwen, Pim J., Donswijk, Maarten, Nandurkar, Rohan, Stricker, Phillip, Ho, Bao, Heijmink, Stijn, Wit, Esther M.K., Tillier, Corinne, Muilenkom, Erik, Nguyen, Quoc, Poel, Henk G., Emmett, Louise
Format: Article
Language:English
Subjects:
accuracy
Aged
Antigens
biochemical recurrence
Cancer surgery
Computed tomography
Gallium
Gallium Radioisotopes
Humans
Lymph Node Excision
Lymph nodes
Lymphatic Metastasis
Lymphatic system
Magnetic resonance imaging
Male
Metastases
Middle Aged
Neoplasm Staging
PCSM
Positron emission tomography
Positron Emission Tomography Computed Tomography
Predictive Value of Tests
Prostate cancer
Prostate-Specific Antigen - blood
ProstateCancer
Prostatectomy
prostate‐specific membrane antigen
Prostatic Neoplasms - blood
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - surgery
radical prostatectomy
Tomography
Urological surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine the value of gallium‐68‐prostate‐specific membrane antigen (68Ga‐PSMA)‐11 positron emission tomography (PET) /computed tomography (CT) in men with newly diagnosed prostate cancer. Patients and methods We analysed results of 140 men with intermediate‐ and high‐risk prostate cancer. All men underwent 68Ga‐PSMA‐11 PET/CT and multiparametric magnetic resonance imaging (mpMRI) before radical prostatectomy (RP) with extended pelvic lymph node (LN) dissection. For each patient, the clinical and pathological features were recorded. Prostate‐specific antigen (PSA) was documented at staging scan, and after RP, at a median (interquartile range) of 110 (49–132) days. A PSA level of ≥0.03 ng/mL was classified as biochemical persistence (BCP). Logistic regression was performed for association of clinical variables and BCP. Results In these 140 patients with intermediate‐ and high‐risk prostate cancer, 27.1% had PSMA PET/CT‐positive findings in the pelvic LNs. Sensitivity and specificity for detection of LN metastases were 53% and 88% (PSMA PET/CT) and 14% and 99% (mpMRI), respectively. The overall BCP rate was 25.7%. The BCP rate was 16.7% in men who were PSMA PET/CT LN‐negative compared to 50% in men who were PSMA PET/CT LN‐positive (P 
ISSN:1464-4096
1464-410X
DOI:10.1111/bju.14506